Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human malignancies and tends to be relatively resistant to conventional therapies. Activated Ras oncogene mutations are found in up to 90% of PDAC, leading to activation of the Ras/Raf/MEK/ERK signaling pathway. Sorafe...

Full description

Saved in:
Bibliographic Details
Main Authors: Awasthi, Niranjan, Zhang, Changhua, Hinz, Stefan, Schwarz, Margaret A, Schwarz, Roderich E
Format: Artigo
Language:Inglês
Published: BioMed Central 2013
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3618297/
https://ncbi.nlm.nih.gov/pubmed/23497499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-9966-32-12
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items